Ipsen is voluntarily withdrawing the cancer drug tazemetostat (Tazverik) from the US and all other markets due to safety concerns[1]. This is due to new data from an ongoing clinical trial that revealed risks of secondary blood cancers and an unfavorable safety profile compared to previous observations[1]. Tazverik is an EZH2 inhibitor approved for follicular lymphoma and epithelial sarcoma[1][6]. Ipsen is terminating all active clinical trials and expanded access programs for the drug across all indications[1]. The company is working with the FDA on a formal recall process in the US[1]. Patient safety is a priority, as stated by Executive Vice President Research and Development Christelle Huguet[1].